Clinical Benefits of Denosumab vs Zoledronate in Postmenopausal Women Previously Treated with Alendronate: A Two-Year Retrospective Study.

Drug Des Devel Ther · 2025 · PMC12630840 · PMID 41281932

Europe PMC DOI

hedged sentences

0.0890

closest p · 1.8× alpha

0.0890

boldest claim

The sentences

showed a trendp = 0.089so close (0.05 < p ≤ 0.1)

In the ZOL group, the incidence of new-onset fractures showed a trend of negative correlation with the percentage change in serum β-CTX level at month 12 (r = −0.135, p = 0.089).

also in 53,322 other papers

a negative trendno p-value reported

28 , 29 In our study, the percentage change (from baseline to month 12) of serum β-CTX had a negative trend to the occurrence of new-onset fracture.

also in 4,201 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.